Surface-modified yeast cells: A novel eukaryotic carrier for oral application

Kenngott, Elisabeth E.; Kiefer, Ruth; Schneider-Daum, Nicole; Schneider, Marc; Breinig, Frank

doi:10.1016/j.jconrel.2015.12.054

Cited by 21 publications

(13 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yeast cells have already been proven to represent an effective delivery vehicle for the specific targeting of phagocytes. Consequently, a nano-in-micro carrier consisting of NP-loaded S. cerevisiae cells would be a promising approach to accomplish an efficient and precise targeting to MΦ (Bazan et al, 2011;Kenngott et al, 2016;Walch et al, 2011Walch et al, , 2012Walch-Rückheim et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

“…Considering the achievements already earned by using nanoparticles for immunotherapy, the combination with yeast cells for specific targeting to APC might lead to a substantial progress in different therapeutic approaches as suggested by Amoozgar and Goldberg (). Beyond the cell‐specific targeting and protection of the cargo, S. cerevisiae offers much more possibilities like modification of the cell surface improving the application via the oral route (Kenngott et al, ) or provoke an antitumor immune response (Liu et al, ). Future experiments using NPs loaded with functional molecules will reveal the full potential of yeast/NP complexes in therapeutic approaches.…”

Section: Discussionmentioning

confidence: 99%

“…Among the different yeast genera, the well‐characterized baker's yeast Saccharomyces cerevisiae possesses the GRAS status facilitating a possible application as a carrier system, thereby providing the advantages of a single cell organism including easy handling and genetic modification. In addition, S. cerevisiae harbors the opportunity of oral delivery as it is able to protect a cargo from degradation by acidic pH or proteases during gastrointestinal passage and is efficiently taken up by specialized M cells in the gut (Beier & Gebert, ; Kenngott et al, ). Furthermore, glucan particles, derived from the cell wall of S. cerevisiae , have already been successfully examined for oral as well as systemic delivery of NPs to macrophages (Soto, Caras, Kut, Castle, & Ostroff, ; Soto & Ostroff, ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Targeted delivery of functionalized PLGA nanoparticles to macrophages by complexation with the yeast Saccharomyces cerevisiae

Kiefer

Jurisic

Dahlem

et al. 2019

Biotech & Bioengineering

Self Cite

View full text Add to dashboard Cite

Nanoparticles (NPs) are able to deliver a variety of substances into eukaryotic cells.However, their usage is often hampered by a lack of specificity, leading to the undesired uptake of NPs by virtually all cell types. In contrast to this, yeast is known to be specifically taken up into immune cells after entering the body. Therefore, we investigated the interaction of biodegradable surface-modified poly(lactic-co-glycolic acid) (PLGA) particles with yeast cells to overcome the unspecificity of the particulate carriers. Cells of different Saccharomyces cerevisiae strains were characterized regarding their interaction with PLGA-NPs under isotonic and hypotonic conditions. The particles were shown to efficiently interact with yeast cells leading to stable NP/ yeast-complexes allowing to associate or even internalize compounds. Notably, applying those complexes to a coculture model of HeLa cells and macrophages, the macrophages were specifically targeted. This novel nano-in-micro carrier system suggests itself as a promising tool for the delivery of biologically active agents into phagocytic cells combining specificity and efficiency.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Targeted delivery of functionalized PLGA nanoparticles to macrophages by complexation with the yeast Saccharomyces cerevisiae

Kiefer

Jurisic

Dahlem

et al. 2019

Biotech & Bioengineering

Self Cite

View full text Add to dashboard Cite

show abstract

“…Caco-2/Raji co-cultivation was established in the Transwell system with a procedure previously described. 48 Transepithelial electrical resistance (TEER) measurement was also used to assess the formation of a cell monolayer with maintenance of tight junction integrity as previously described. 49 Only wells with TEER values of at least 0.3 kΩ/cm 2 were used in permeation experiments.…”

Section: Methodsmentioning

confidence: 99%

Thermoresponsive Bacteriophage Nanocarrier as a Gene Delivery Vector Targeted to the Gastrointestinal Tract

Namdee

Khongkow

Boonrungsiman

et al. 2018

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

The use of the gastrointestinal tract as a site for the local delivery of DNA is an exciting prospect. In order to obtain an effective vector capable of delivering a gene of interest to target cells to achieve sufficient and sustained transgene expression, with minimal toxicity, we developed a new generation of filamentous bacteriophage. This particular bacteriophage was genetically engineered to display an arginine-glycine-aspartic acid (RGD) motif (an integrin-binding peptide) on the major coat protein pVIII and carry a mammalian DNA cassette. One unanticipated observation is the thermoresponsive behavior of engineered bacteriophage. This finding has led us to simplify the isolation method to purify bacteriophage particles from cell culture supernatant by low-temperature precipitation. Our results showed that, in contrast to non-surface modified, the RGD-modified bacteriophage was successfully used to deliver a transgene to mammalian cells. Our in vitro model of the human intestinal follicle-associated epithelium also demonstrated that bacteriophage particles were stable in simulated gastrointestinal fluids and able to cross the human intestinal barrier. In addition, we confirmed an adjuvant property of the engineered bacteriophage to induce nitric oxide production by macrophages. In conclusion, our study demonstrated the possibility of using bacteriophage for gene transfer in the gastrointestinal tract.

show abstract

“…M-like models have been applied to study of basic physiology, selection of ligands and simulation of pathogen transport 234 , 248 , 256 . In recent years, the models have been well adapted for prediction of enteric uptake of biomacromolecules and particulates 160 , 257 , 258 . Nevertheless, in vitro models should not be utilized to replace in vivo models because of the simplified cell monolayer structures and presence of excessively high content of M-like cells which may lead to overestimation of experimental results 259 .…”

Section: Models For Evaluation Of Lymphatic Transportmentioning

confidence: 99%

An update on oral drug delivery via intestinal lymphatic transport

Zi-chen

Lü

et al. 2021

Acta Pharmaceutica Sinica B

111

View full text Add to dashboard Cite

Orally administered drug entities have to survive the harsh gastrointestinal environment, penetrate the enteric epithelia and circumvent hepatic metabolism before reaching the systemic circulation. Whereas the gastrointestinal stability can be well maintained by taking proper measures, hepatic metabolism presents as a formidable barrier to drugs suffering from first-pass metabolism. The pharmaceutical academia and industries are seeking alternative pathways for drug transport to circumvent problems associated with the portal pathway. Intestinal lymphatic transport is emerging as a promising pathway to this end. In this review, we intend to provide an updated overview on the rationale, strategies, factors and applications involved in intestinal lymphatic transport. There are mainly two pathways for peroral lymphatic transport—the chylomicron and the microfold cell pathways. The underlying mechanisms are being unraveled gradually and nowadays witness increasing research input and applications.

show abstract

Surface-modified yeast cells: A novel eukaryotic carrier for oral application

Cited by 21 publications

References 47 publications

Targeted delivery of functionalized PLGA nanoparticles to macrophages by complexation with the yeast Saccharomyces cerevisiae

Targeted delivery of functionalized PLGA nanoparticles to macrophages by complexation with the yeast Saccharomyces cerevisiae

Thermoresponsive Bacteriophage Nanocarrier as a Gene Delivery Vector Targeted to the Gastrointestinal Tract

An update on oral drug delivery via intestinal lymphatic transport

Contact Info

Product

Resources

About